focus -WSS

focus

author：entertainment 2025-09-06 02:08:13 - browse：23854

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Pfizer plans to depart BIO

WSS

David Sabatini, ex

What causes an itch? Researchers may have solved the mystery

Pregnancy discrimination could be enabled by AI

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

focus

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Tori Bowie and the unacceptable rates of Black maternal death

Chemotherapy shortages won’t get better under Biden’s latest plan

New air purifier tech could be key to improving indoor air quality

Childhood cancer progress stalls for Black, Hispanic kids: Report

Jerome Adams on the need for new antivirals for Covid

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Activists slam private health insurers over coverage restrictions

What PEPFAR has meant on the ground in Ukraine

entertainment

FDA's Woodcock to retire early next year

Why sickle cell disease is getting the first CRISPR treatment

A daunting task: navigating dual Medicare, Medicaid eligibility

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Hospitals look to new technology to keep health care workers safe

David Sabatini, ex

leisure time

focus

hotspot

Wikipedia